IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies. We are applying these capabilities across three classes of precision medicine: direct targeting of oncogenic pathways, synthetic lethality – which represents an emerging class of precision medicine targets – and immuno-oncology. This diversified approach enables our objective to deliver the right medicine to the right patient to drive a more robust clinical response. IDEAYA, headquartered in South San Francisco, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology, small molecule drug discovery, translational biology and clinical development.
”IDEAYA was founded with the premise that attracting the industry's best scientists and focusing on areas of transformative research is a proven model for delivering game-changing medicines to patients. Our people are passionate and proven cancer biologists, translational biologists, drug discovery chemists and development professionals. As an organization, we believe that our entrepreneurial spirit and nimbleness, and commitment to foster innovation, teamwork and excellence is what sets us apart. Our greatest asset is our scientists and their passion to discover innovative new therapies for cancer patients.Yujiro S. HataIDEAYA Chief Executive Officer